Coumarins, naturally occurring benzopyrones, have garnered significant attention due to their diverse pharmacological activities and therapeutic potential. Derived from natural sources and synthetic routes such as the Perkin and Pechmann reactions, these compounds exhibit a broad spectrum of biological activities, including antioxidant, anti-inflammatory, antimicrobial, anticancer, antidiabetic, and neuroprotective effects. The structure-activity relationship of coumarins highlights the critical role of substitutions at specific positions on the benzopyrone ring, enhancing their efficacy and selectivity. Notable applications include anticancer activities, with coumarin derivatives inhibiting tumor growth and inducing apoptosis in breast cancer and melanoma cells, and neuroprotection, particularly in Alzheimer's and Parkinson’s diseases, through acetylcholinesterase inhibition and β- amyloid modulation. Additionally, coumarins show promise in combating drug-resistant pathogens and oxidative stress. Despite their potential, challenges such as toxicity and bioavailability remain. Future research should focus on optimizing coumarin scaffolds and advancing clinical evaluations to establish their role as next-generation therapeutic agents.

In nanoemulsions, both oil and water droplets are stabilised by an amphiphilic surfactant. Ultrafine dispersions with varying drug loading, viscoelastic properties, and aesthetic characteristics may be useful for the administration of medication. A 20-500-nanometer droplet size range for nanoemulsions has been established. The biological behavior of a nanoemulsions formulation is heavily influenced by its droplet diameter and surface properties. Small droplet size results in clear emulsions; therefore, the appearance of the product is unaffected even by the addition of an oil phase. Nanoemulsions are oil-in-water dispersions that are transparent or translucent and are stabi-lized by an interfacial layer of surfactants and cosurfactant particles with droplet size smaller than 100 nm. New nanoscience-based technologies are becoming increasingly popular as a means of im-proving food safety, quality, and nutrition. In this field, nanoemulsions have been a key focus since they can be readily manufactured using current food components and technology. Food nanoemul-sions, which are tiny oil droplets distributed in water, are being used as delivery methods for a vari-ety of hydrophobic compounds, including nutrients, nutraceuticals, antioxidants, and antimicrobial agents. The present review is focused on the formulation, characterization, and applications of nanoemulsions.

Millions of people worldwide suffer from Alzheimer's disease (AD), a progressive neurological illness whose incidence is rising as the population ages. Since existing medicines are ineffective and mainly treat symptoms rather than delaying the course of the disease, recent research conducted in 2023 and 2024 highlights the urgent need for novel therapeutic methods. Because of its adaptable chemical structure, which enables it to interact with important enzymes and receptors involved in AD disease, the pyrazole moiety has garnered significant attention in Alzheimer's research. The ability of recent developments in the synthesis of pyrazole derivatives to inhibit the enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), which are linked to cognitive impairment in AD, has shown promise. These novel compounds may be used as multitarget therapies for AD because several of them also have anti-inflammatory, anti-amyloid, and antioxidant properties. These pyrazole-based substances have demonstrated neuroprotective benefits in preclinical studies by lowering the generation of amyloid-beta plaque and shielding neurons from oxidative stress, two important processes in the development of AD. Pyrazole-based drugs may prove to be a useful addition to AD therapy choices as researchers work to improve these derivatives for increased bioavailability and fewer adverse effects. These advancements give patients hope and move the quest for disease-modifying medications closer to more potent treatments that target the intricate pathways underlying Alzheimer's disease.

Background: Fungal infections are opportunistic infections that become a serious problem for human health. Objective: Considering the antifungal potential of the triazole nucleus, the study was carried out with the objective of synthesizing some novel triazole derivatives with antifungal potential. Methods: 1,2,4-triazole derivatives were synthesized via a two-step reaction (reported earlier). The first step involves the reaction of substituted benzoic acid with thiocarbohydrazide to form 4- amino-3-(substituted phenyl)-5-mercapto-1, 2, 4-triazole derivatives (1a-1k) while in the second step, synthesized compounds (1a-1k) were then subsequently treated with substituted acetophenone to yield substituted (4-methoxyphenyl-7H-[1, 2, 4] triazolo [3, 4-b][1,3,4] thiadiazine derivatives (2a-2k). All synthesized compounds were characterized by IR, 1H NMR, and Mass spectral data analysis and were screened for their antifungal properties against different fungal strains i.e. Candida tropicalis (ATCC-13803, ATCC-20913), Candida albicans (ATCC-60193), Candida inconspicua (ATCC-16783) and Candida glabrata (ATCC-90030, ATCC-2001). Results: Compound 2d displayed better percentage inhibition (26.29%, 24.81%) than fluconazole (24.44%, 22.96%) against ATCC-16783, ATCC-2001 fungal strains respectively at 100μg/ml. Compound 2f also displayed better percentage inhibition (28.51%) against ATCC-90030 as compared to fluconazone (27.4%) at 200 μg/ml. Similarly, compounds 2e and 2j also exhibited better antifungal properties than fluconazole at 200μg/ml. Compound 2e was found most potent against ATCC-13803 (30.37%) and ATCC-90030 (30.37%) fungal strains as compared to fluconazole (28.14%, 27.4%) at 200 μg/ml respectively whereas compound 2j exhibited better antifungal activity (28.51%) against ATCC-60193 than fluconazole (27.7%) at 200 μg/ml. Conclusion: The results were in accordance with our assertions for triazole derivatives, as all compounds displayed moderate to good antifungal activity.

: Leukaemia, lymphoma, and myeloma are among the serious and frequently fatal conditions that impact thousands of people each year. Genetics, environmental factors, and medical problems can all affect the risk of developing blood cancer, however, the precise causes are still not entirely known. Fatigue, unexpected weight loss, and frequent infections are examples of common blood cancer symptoms. In the course of the diagnosis process, blood tests, imaging tests, and bone marrow biopsies are frequently combined. Blood cancer therapies include chemotherapy, radiation therapy, stem cell transplant, targeted therapy, and immunotherapy. Supportive care is also important for managing symptoms and improving quality of life. Ongoing research is exploring new treatments and therapies for blood cancer, as well as ways to improve supportive care and personalize treatment plans. Blood cancer patients and their families have severe emotional and psychological effects that must not be ignored. For improving outcomes and raising the general standard of living for people affected by this condition, it is essential to address these needs.